Background illustration for clinical trials search

Paid Clinical Trials Norman

Discover 568 paid clinical trials in Norman, Oklahoma. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 568

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

for

Locally Advanced Cervical Adenocarcinoma,

Location: Oklahoma City OK, Tulsa OK, Richardson TX, Dallas TX,

Sponsor: National Cancer Institute (NCI)

Sex: Female

Age: 18+

Code: NCT07061977

Phase3, Recruiting

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

for

Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular,

Location: Oklahoma City OK, Fort Worth TX, Dallas TX, Lubbock TX,

Sponsor: Children's Oncology Group

Sex: All

Age: 1 - 30

Code: NCT03126916

Phase3, Recruiting

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

for

Extensive Stage Lung Small Cell Carcinoma,

Location: Oklahoma City OK, Salina KS, Olathe KS,

Sponsor: SWOG Cancer Research Network

Sex: All

Age: 18+

Code: NCT06769126

Phase2, Recruiting

Enhancing Smoking Cessation for African American People Everywhere

for

ESCAPE Intervention+NRT, quitSTART Intervention+NRT, CTRL+NRT

Location: Oklahoma City OK

Sponsor: University of Houston

Sex: All

Age: 18+

Code: NCT07024992

Phase2, Recruiting

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

for

Lung Non-Small Cell Carcinoma

Location: Oklahoma City OK, Cape Girardeau MO, O'Fallon IL,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT07388524

Phase3, Recruiting

A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)

for

Ulcerative Colitis, Crohn's Disease

Location: Oklahoma City OK

Sponsor: Takeda

Sex: All

Age: 2 - 17

Code: NCT06405087

Phase3, Recruiting

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

for

Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia

Location: Oklahoma City OK, Wellington KS, Winfield KS,

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All

Age: 65+

Code: NCT07321652

Phase3, Recruiting

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

for

Muscle Invasive Bladder Urothelial Carcinoma,

Location: Oklahoma City OK, Richardson TX, Dallas TX,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT07061964

Phase2, Recruiting

Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)

for

Core Binding Factor Acute Myeloid Leukemia

Location: Oklahoma City OK, Overland Park KS, Fairway KS,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18 - 59

Code: NCT06917911

Phase2, Recruiting

Empowering Cessation ACS South Region

for

Smoking Cessation

Location: Oklahoma City OK

Sponsor: University of Oklahoma

Sex: All

Age: 18 - 70+

Code: NCT06820034

Phase2, Phase3, Recruiting

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

for

Endometrial Adenocarcinoma,

Location: Oklahoma City OK, Richardson TX, Dallas TX,

Sponsor: National Cancer Institute (NCI)

Sex: Female

Age: 18+

Code: NCT05112601

Phase2, Recruiting

Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers

for

Pancreatic Neoplasm

Location: Oklahoma City OK, Dallas TX, Little Rock AR, Houston TX,

Sponsor: ECOG-ACRIN Cancer Research Group

Sex: All

Age: 50 - 70+

Code: NCT04239573

Recruiting

The Vanguard Study: Testing a New Way to Screen for Cancer

for

Bladder Carcinoma, Breast Carcinoma, Colorectal Carcinoma,

Location: Oklahoma City OK, Kansas City MO, Cheyenne Wells CO,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 45 - 70+

Code: NCT06995898

Recruiting

E-Mindfulness Approaches for Living After Breast Cancer

for

Breast Cancer, Depression

Location: Oklahoma City OK, Fort Smith AR, Amarillo TX,

Sponsor: NRG Oncology

Sex: All

Age: 18 - 50

Code: NCT06748222

Phase3, Recruiting

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

for

Prostate Cancer (Adenocarcinoma)

Location: Oklahoma City OK, Lawton OK, Dallas TX,

Sponsor: Canadian Cancer Trials Group

Sex: Male

Age: 18+

Code: NCT06592924

Phase3, Recruiting

Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy

for

Recurrent Non-Muscle Invasive Bladder Carcinoma,

Location: Oklahoma City OK, Metairie LA, Cheyenne WY,

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All

Age: 18+

Code: NCT07000084

Phase3, Recruiting

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

for

Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia

Location: Oklahoma City OK, Tulsa OK, Dallas TX, Fort Worth TX,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 1 - 30

Code: NCT04546399

Phase2, Recruiting

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

for

Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8,

Location: Oklahoma City OK, Salina KS, Westwood KS,

Sponsor: NRG Oncology

Sex: All

Age: 18+

Code: NCT06532279

Phase2, Recruiting

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

for

High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements,

Location: Oklahoma City OK, Bellevue NE, Omaha NE,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06649812

Phase2, Recruiting

A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

for

Malignant Glioma

Location: Oklahoma City OK, Dallas TX, Fort Worth TX,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 1 - 21

Code: NCT05099003

Phase1, Phase2, Recruiting

Paid Clinical Trials Norman

Filter results

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

Enhancing Smoking Cessation for African American People Everywhere

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

Interested in new trials?

A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)

Empowering Cessation ACS South Region

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers

The Vanguard Study: Testing a New Way to Screen for Cancer

E-Mindfulness Approaches for Living After Breast Cancer

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)